View in EDS HTML Full Text PDF Full Text

Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems.

Saved in:
Bibliographic Details
Title: Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems.
Authors: Isoardi, Katherine Z. (AUTHOR), Alfred, Sam (AUTHOR), Weber, Courtney (AUTHOR), Harris, Keith (AUTHOR), Soderstrom, Jessamine (AUTHOR), Syrjanen, Rebekka (AUTHOR), Thompson, Amanda (AUTHOR), Schumann, Jennifer (AUTHOR), Stockham, Peter (AUTHOR), Sakrajda, Paul (AUTHOR), Fatovich, Daniel (AUTHOR), Greene, Shaun L. (AUTHOR)
Source: Drug & Alcohol Review. Jan2026, Vol. 45 Issue 1, p1-6. 6p.
Subjects: Opioids, Naloxone, Hospital emergency services, Toxicity testing, Drug toxicity, Designer drugs
Geographic Terms: Australia
Abstract: Introduction: Nitazenes are a group of potent synthetic opioids that have had increasing prominence as novel psychoactive drugs in the last 5 years. We describe emergency department nitazene‐related presentations. Methods: This is a prospective series of patients with analytically confirmed nitazene presentations identified by the Emerging Drugs Network of Australia and Emerging Drugs Network of Australia Victoria. Both studies' databases were searched between July 2020 and February 2024 with clinical data and blood nitazene concentrations abstracted. Results: There were 32 presentations, 23 (72%) males, with a median age of 31 years (range 18–63 years). Only five (16%) intentionally ingested a nitazene, with most (12, 38%) believing they had taken alternative opioids. Co‐exposures occurred in 31 (97%), mostly metamfetamine. Naloxone was administered in 23 (72%) presentations, with a median total dose of intravenous naloxone within 1 h post hospital presentation of 400 μg (interquartile range [IQR] 160–450 μg). Four (13%) received a naloxone infusion. Thirteen (41%) were admitted to the intensive care unit. The median length of stay was 17 h (IQR 7–39 h). Protonitazene was the commonest nitazene detected in 23 (72%) presentations with a median concentration of 2.0 μg/L (range 0.7–15 μg/L). The lowest concentration of protonitazene in a patient that received naloxone was 0.7 μg/L. Discussion and Conclusions: Most patients were unaware they were using nitazenes. Given their potency, this has important implications for harm, particularly in those not intentionally using opioids. Nitazene exposure was mostly unintentional. Naloxone use was common and standard dosing regimens appeared effective in most cases. [ABSTRACT FROM AUTHOR]
Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 191183402
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Isoardi%2C+Katherine+Z%2E%22">Isoardi, Katherine Z.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alfred%2C+Sam%22">Alfred, Sam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weber%2C+Courtney%22">Weber, Courtney</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Harris%2C+Keith%22">Harris, Keith</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Soderstrom%2C+Jessamine%22">Soderstrom, Jessamine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Syrjanen%2C+Rebekka%22">Syrjanen, Rebekka</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thompson%2C+Amanda%22">Thompson, Amanda</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schumann%2C+Jennifer%22">Schumann, Jennifer</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stockham%2C+Peter%22">Stockham, Peter</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sakrajda%2C+Paul%22">Sakrajda, Paul</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fatovich%2C+Daniel%22">Fatovich, Daniel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Greene%2C+Shaun+L%2E%22">Greene, Shaun L.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Drug+%26+Alcohol+Review%22">Drug & Alcohol Review</searchLink>. Jan2026, Vol. 45 Issue 1, p1-6. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Opioids%22">Opioids</searchLink><br /><searchLink fieldCode="DE" term="%22Naloxone%22">Naloxone</searchLink><br /><searchLink fieldCode="DE" term="%22Hospital+emergency+services%22">Hospital emergency services</searchLink><br /><searchLink fieldCode="DE" term="%22Toxicity+testing%22">Toxicity testing</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+toxicity%22">Drug toxicity</searchLink><br /><searchLink fieldCode="DE" term="%22Designer+drugs%22">Designer drugs</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Australia%22">Australia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: Nitazenes are a group of potent synthetic opioids that have had increasing prominence as novel psychoactive drugs in the last 5 years. We describe emergency department nitazene‐related presentations. Methods: This is a prospective series of patients with analytically confirmed nitazene presentations identified by the Emerging Drugs Network of Australia and Emerging Drugs Network of Australia Victoria. Both studies' databases were searched between July 2020 and February 2024 with clinical data and blood nitazene concentrations abstracted. Results: There were 32 presentations, 23 (72%) males, with a median age of 31 years (range 18–63 years). Only five (16%) intentionally ingested a nitazene, with most (12, 38%) believing they had taken alternative opioids. Co‐exposures occurred in 31 (97%), mostly metamfetamine. Naloxone was administered in 23 (72%) presentations, with a median total dose of intravenous naloxone within 1 h post hospital presentation of 400 μg (interquartile range [IQR] 160–450 μg). Four (13%) received a naloxone infusion. Thirteen (41%) were admitted to the intensive care unit. The median length of stay was 17 h (IQR 7–39 h). Protonitazene was the commonest nitazene detected in 23 (72%) presentations with a median concentration of 2.0 μg/L (range 0.7–15 μg/L). The lowest concentration of protonitazene in a patient that received naloxone was 0.7 μg/L. Discussion and Conclusions: Most patients were unaware they were using nitazenes. Given their potency, this has important implications for harm, particularly in those not intentionally using opioids. Nitazene exposure was mostly unintentional. Naloxone use was common and standard dosing regimens appeared effective in most cases. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=191183402
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/dar.13998
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 1
    Subjects:
      – SubjectFull: Opioids
        Type: general
      – SubjectFull: Naloxone
        Type: general
      – SubjectFull: Hospital emergency services
        Type: general
      – SubjectFull: Toxicity testing
        Type: general
      – SubjectFull: Drug toxicity
        Type: general
      – SubjectFull: Designer drugs
        Type: general
      – SubjectFull: Australia
        Type: general
    Titles:
      – TitleFull: Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Isoardi, Katherine Z.
      – PersonEntity:
          Name:
            NameFull: Alfred, Sam
      – PersonEntity:
          Name:
            NameFull: Weber, Courtney
      – PersonEntity:
          Name:
            NameFull: Harris, Keith
      – PersonEntity:
          Name:
            NameFull: Soderstrom, Jessamine
      – PersonEntity:
          Name:
            NameFull: Syrjanen, Rebekka
      – PersonEntity:
          Name:
            NameFull: Thompson, Amanda
      – PersonEntity:
          Name:
            NameFull: Schumann, Jennifer
      – PersonEntity:
          Name:
            NameFull: Stockham, Peter
      – PersonEntity:
          Name:
            NameFull: Sakrajda, Paul
      – PersonEntity:
          Name:
            NameFull: Fatovich, Daniel
      – PersonEntity:
          Name:
            NameFull: Greene, Shaun L.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 09595236
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Drug & Alcohol Review
              Type: main
ResultId 1